Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Starpharma Holdings Provides Response to ASX Aware Letter

07 Jan 2019  |  17:18:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Response to ASX Aware Letter

Starpharma Holdings provided response to ASX stating that it does consider the information in the US FDA Announcement to be information that a reasonable person would expect to have a material effect on the price or value of its securities. The Company updated that it received a copy of the FDA notification via email from US regulatory representative on 27 December 2018. As reported, the Company does not consider that the information in the Japanese PMDA Announcement was likely to have a material effect on the price or value of its securities. The Company further confirmed that it is complying with the Listing Rules, in particular, Listing Rule 3.1.

Please click here for full details

See more ASX300 News Announcements